Kwok‐Kin Wong

The paper shows cancer cells adapt along a proliferation-robustness axis in response to TME components, leading to pro-tumor phenotypes.

This study identifies M1C as a driver of sotorasib resistance in NSCLC KRAS G12C mutant tumors and shows that targeting M1C improves treatment outcomes.

This study shows that aneuploidy promotes ROS resistance by suppressing PARP1, which enhances metastasis, and identifies CEBPB as a key mediator of this process.

This study shows that a dual inhibitor of KRASG12C in both ON and OFF states more effectively suppresses tumor growth than an OFF-specific inhibitor by reducing PI3K-AKT activation.

This study identifies KEAP1 loss as a resistance mechanism to KRAS inhibitors in pancreatic and lung cancer and shows that combining glutamine inhibition with KRAS inhibitors can overcome this resistance.

This paper introduces DD-CIPs, bivalent molecules that induce DNA damage response and apoptosis in cancer cells, showing efficacy against PARPi-resistant cancers.

This study shows that inhibiting DNA polymerase epsilon in TNBC triggers an NF-κB-driven inflammatory response and tumor clearance in mice.

This study identifies genotype-specific immune and metabolic vulnerabilities in lung adenocarcinoma through cross-species analysis of human and mouse tumors.

This study identifies EGFR mutations conferring resistance to BLU-945 using deep mutational scanning and shows that combination treatment may suppress resistance mechanisms.

The paper introduces a segmentation-free vision transformer, CANVAS, to discover and characterize tumor microenvironment signatures from high-dimensional multiplexed images, identifying a monocytic signature linked to poor prognosis.

The paper identifies adeno-to-squamous transition (AST) as a mechanism of resistance to KRAS inhibitors in LKB1 mutant lung cancer and links KRT6A expression to poor patient outcomes.

This study identifies inflammation in tumor-adjacent lung tissue as a predictor of clinical outcome in lung adenocarcinoma using multi-omic analysis of 143 stage I cases.